211 related articles for article (PubMed ID: 16484444)
1. Cytoplasmic overexpression of ALCAM is prognostic of disease progression in breast cancer.
Burkhardt M; Mayordomo E; Winzer KJ; Fritzsche F; Gansukh T; Pahl S; Weichert W; Denkert C; Guski H; Dietel M; Kristiansen G
J Clin Pathol; 2006 Apr; 59(4):403-9. PubMed ID: 16484444
[TBL] [Abstract][Full Text] [Related]
2. ALCAM/CD166 is overexpressed in colorectal carcinoma and correlates with shortened patient survival.
Weichert W; Knösel T; Bellach J; Dietel M; Kristiansen G
J Clin Pathol; 2004 Nov; 57(11):1160-4. PubMed ID: 15509676
[TBL] [Abstract][Full Text] [Related]
3. Biologic role of activated leukocyte cell adhesion molecule overexpression in breast cancer cell lines and clinical tumor tissue.
Hein S; Müller V; Köhler N; Wikman H; Krenkel S; Streichert T; Schweizer M; Riethdorf S; Assmann V; Ihnen M; Beck K; Issa R; Jänicke F; Pantel K; Milde-Langosch K
Breast Cancer Res Treat; 2011 Sep; 129(2):347-60. PubMed ID: 20972617
[TBL] [Abstract][Full Text] [Related]
4. Membranous expression of activated leukocyte cell adhesion molecule contributes to poor prognosis and malignant phenotypes of non-small-cell lung cancer.
Ishiguro F; Murakami H; Mizuno T; Fujii M; Kondo Y; Usami N; Taniguchi T; Yokoi K; Osada H; Sekido Y
J Surg Res; 2013 Jan; 179(1):24-32. PubMed ID: 22985775
[TBL] [Abstract][Full Text] [Related]
5. Aldehyde dehydrogenase 1 expression is a predictor of poor prognosis in node-positive breast cancers: a long-term follow-up study.
Yoshioka T; Umekita Y; Ohi Y; Souda M; Sagara Y; Sagara Y; Sagara Y; Rai Y; Tanimoto A
Histopathology; 2011 Mar; 58(4):608-16. PubMed ID: 21371077
[TBL] [Abstract][Full Text] [Related]
6. Activated leukocyte cell adhesion molecule (CD166)--its prognostic power for colorectal cancer patients.
Tachezy M; Zander H; Gebauer F; Marx A; Kaifi JT; Izbicki JR; Bockhorn M
J Surg Res; 2012 Sep; 177(1):e15-20. PubMed ID: 22482754
[TBL] [Abstract][Full Text] [Related]
7. Predictive impact of activated leukocyte cell adhesion molecule (ALCAM/CD166) in breast cancer.
Ihnen M; Müller V; Wirtz RM; Schröder C; Krenkel S; Witzel I; Lisboa BW; Jänicke F; Milde-Langosch K
Breast Cancer Res Treat; 2008 Dec; 112(3):419-27. PubMed ID: 18172759
[TBL] [Abstract][Full Text] [Related]
8. Expression of the cell to cell adhesion molecule, ALCAM, in breast cancer patients and the potential link with skeletal metastasis.
Davies SR; Dent C; Watkins G; King JA; Mokbel K; Jiang WG
Oncol Rep; 2008 Feb; 19(2):555-61. PubMed ID: 18202807
[TBL] [Abstract][Full Text] [Related]
9. Immunophenotypic analysis of inflammatory breast cancers: identification of an 'inflammatory signature'.
Charafe-Jauffret E; Tarpin C; Bardou VJ; Bertucci F; Ginestier C; Braud AC; Puig B; Geneix J; Hassoun J; Birnbaum D; Jacquemier J; Viens P
J Pathol; 2004 Mar; 202(3):265-73. PubMed ID: 14991891
[TBL] [Abstract][Full Text] [Related]
10. CD24 expression is a new prognostic marker in breast cancer.
Kristiansen G; Winzer KJ; Mayordomo E; Bellach J; Schlüns K; Denkert C; Dahl E; Pilarsky C; Altevogt P; Guski H; Dietel M
Clin Cancer Res; 2003 Oct; 9(13):4906-13. PubMed ID: 14581365
[TBL] [Abstract][Full Text] [Related]
11. Subcellular localization of activated leukocyte cell adhesion molecule is a molecular predictor of survival in ovarian carcinoma patients.
Mezzanzanica D; Fabbi M; Bagnoli M; Staurengo S; Losa M; Balladore E; Alberti P; Lusa L; Ditto A; Ferrini S; Pierotti MA; Barbareschi M; Pilotti S; Canevari S
Clin Cancer Res; 2008 Mar; 14(6):1726-33. PubMed ID: 18347173
[TBL] [Abstract][Full Text] [Related]
12. Increased expression of osteopontin in patients with triple-negative breast cancer.
Wang X; Chao L; Ma G; Chen L; Tian B; Zang Y; Sun J
Eur J Clin Invest; 2008 Jun; 38(6):438-46. PubMed ID: 18452545
[TBL] [Abstract][Full Text] [Related]
13. Reduced nuclear expression of transcription factor AP-2 associates with aggressive breast cancer.
Pellikainen J; Kataja V; Ropponen K; Kellokoski J; Pietiläinen T; Böhm J; Eskelinen M; Kosma VM
Clin Cancer Res; 2002 Nov; 8(11):3487-95. PubMed ID: 12429639
[TBL] [Abstract][Full Text] [Related]
14. Activated leukocyte cell adhesion molecule is a marker for thyroid carcinoma aggressiveness and disease-free survival.
Chaker S; Kak I; MacMillan C; Ralhan R; Walfish PG
Thyroid; 2013 Feb; 23(2):201-8. PubMed ID: 23148625
[TBL] [Abstract][Full Text] [Related]
15. COX-2 expression in human breast carcinomas: correlation with clinicopathological features and prognostic molecular markers.
Miglietta A; Toselli M; Ravarino N; Vencia W; Chiecchio A; Bozzo F; Motta M; Torchio B; Bocca C
Expert Opin Ther Targets; 2010 Jul; 14(7):655-64. PubMed ID: 20536410
[TBL] [Abstract][Full Text] [Related]
16. Loss of ALCAM expression is linked to adverse phenotype and poor prognosis in breast cancer: a TMA-based immunohistochemical study on 2,197 breast cancer patients.
Burandt E; Bari Noubar T; Lebeau A; Minner S; Burdelski C; Jänicke F; Müller V; Terracciano L; Simon R; Sauter G; Wilczak W; Lebok P
Oncol Rep; 2014 Dec; 32(6):2628-34. PubMed ID: 25270339
[TBL] [Abstract][Full Text] [Related]
17. ALCAM/CD166 protects breast cancer cells against apoptosis and autophagy.
Jezierska A; Matysiak W; Motyl T
Med Sci Monit; 2006 Aug; 12(8):BR263-73. PubMed ID: 16865058
[TBL] [Abstract][Full Text] [Related]
18. Prognostic significance of ALCAM (CD166/MEMD) expression in cutaneous melanoma patients.
Donizy P; Zietek M; Halon A; Leskiewicz M; Kozyra C; Matkowski R
Diagn Pathol; 2015 Jul; 10():86. PubMed ID: 26134500
[TBL] [Abstract][Full Text] [Related]
19. RhoC-GTPase is a novel tissue biomarker associated with biologically aggressive carcinomas of the breast.
Kleer CG; Griffith KA; Sabel MS; Gallagher G; van Golen KL; Wu ZF; Merajver SD
Breast Cancer Res Treat; 2005 Sep; 93(2):101-10. PubMed ID: 16187229
[TBL] [Abstract][Full Text] [Related]
20. HOXB9 expression promoting tumor cell proliferation and angiogenesis is associated with clinical outcomes in breast cancer patients.
Seki H; Hayashida T; Jinno H; Hirose S; Sakata M; Takahashi M; Maheswaran S; Mukai M; Kitagawa Y
Ann Surg Oncol; 2012 Jun; 19(6):1831-40. PubMed ID: 22396001
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]